Histogen Inc Stock Price, News & Analysis

Amerimmune LLC has announced its decision to continue the development of caspase inhibitors for treating COVID-19 and related post-viral syndrome symptoms, following the termination of its agreement with Histogen Inc. on January 2, 2023. The termination allows Amerimmune to focus on research and clinical trials, building on successful Phase 1 study results from early 2021 that indicated safety and potential efficacy. The company is also exploring partnerships for novel caspase inhibitors, indicating a proactive approach in the biotechnology sector. This pivot may positively impact Amerimmune's future developments in orphan disease indications.

Histogen Inc. (NASDAQ: HSTO) announced the appointment of Dr. Alfred P. Spada as Executive Vice President and Chief Scientific Officer. Dr. Spada, an expert in apoptosis and caspase inhibitors, brings over 35 years of industry experience, previously serving as CEO of Aya Biosciences and co-founder of Conatus Pharmaceuticals. His expertise aligns with Histogen’s focus on developing pan-caspase and caspase selective inhibitors for infectious and inflammatory diseases. The company is advancing clinical trials for emricasan, targeting bacterial skin infections.

Histogen Inc. (NASDAQ: HSTO) reported its Q3 2022 financial results, noting significant developments in its clinical pipeline. The company recognized $0 in product revenues, down from $0.9 million year-over-year, while license revenue surged to $3.8 million due to a one-time payment linked to a partnership with Allergan. R&D expenses decreased to $3.9 million, while G&A expenses rose to $7.5 million. Histogen has $14.6 million in cash, sufficient to meet needs through December 2023. Key projects include emricasan for MRSA and the HST 003 study for cartilage regeneration.

Histogen Inc. (NASDAQ: HSTO) announced its second-quarter financial results and updates on clinical programs. The company closed a $5 million financing in July 2022, bolstering cash reserves to $12.6 million as of June 30, 2022. Histogen regained compliance with Nasdaq's minimum bid price requirement after a 1-for-20 reverse stock split. While revenue from product sales declined from $0.3 million in 2021 to $0 in 2022, license revenues increased to $3.8 million due to a one-time payment from Allergan. R&D expenses decreased to $3 million, supporting ongoing projects in spinal disc regeneration and MRSA treatments.

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, will release its financial results for Q2 2022 on August 11, 2022, following market close. The company focuses on developing restorative therapeutics and caspase inhibitors for infectious and inflammatory diseases. Key product candidates include HST-003 for joint cartilage repair and HST-004 for spinal disc repair. Emricasan, developed with Amerimmune, targets COVID-19 and other infections. The pipeline also includes preclinical candidates CTS-2090 and CTS-2096.

Histogen (HSTO) recently completed a private placement, raising approximately $5 million through the sale of 1,774,309 shares of common stock and associated warrants, priced at $2.818 per share. The Series A and B warrants, both exercisable at $2.568 per share, will be available for five and a half years and eighteen months, respectively. The proceeds will be utilized for working capital and corporate purposes. Additionally, certain existing warrants will be amended to reduce the exercise price and extend expiration dates, further incentivizing investors.

Histogen Inc. (NASDAQ: HSTO) announced a securities purchase agreement for a private placement with a healthcare-focused institutional investor. The deal involves issuing 1,774,309 shares of common stock and associated warrants at a price of $2.818 per share, aiming for gross proceeds of approximately $5 million. The Series A and B warrants will have an exercise price of $2.568, and the closing is expected on July 15, 2022. The proceeds will be utilized for working capital and corporate purposes. H.C. Wainwright & Co. is the exclusive placement agent.

Histogen Inc. (NASDAQ: HSTO) announced a 1-for-20 reverse stock split, effective June 2, 2022, at 4:01 p.m. ET. This decision was approved by the Board of Directors and shareholders to reduce the total shares outstanding and increase the market price, ensuring compliance with Nasdaq's listing requirements. Post-split, 20 existing shares will convert to one new share, without affecting shareholders' rights. Fractional shares will be compensated in cash. The new CUSIP number will be 43358Y202, and trading on a split-adjusted basis starts June 3, 2022.

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, will have its Executive Chairman, Steven J. Mento, Ph.D., present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 a.m. Eastern Time. The presentation will focus on their innovative therapeutic developments for infectious and inflammatory diseases. It will be available on-demand and archived for 90 days on Histogen's investor page. Histogen is advancing treatments such as HST-003 for cartilage repair and emricasan for COVID-19 and other diseases.